KITLG and cancer: As the SCF complex is critical for eliciting an effective DNA damage response, perhaps co-treatment with a low-dose SKP1/SCF complex inhibitor would further sensitize cancer cells and synergize with standard chemotherapies to improve response rates and patient outcomes.